You are viewing: Europe Cancer Biomarkers Market analysis
Part of: Cancer Biomarkers Market (Global)

The Europe Cancer Biomarkers Market was valued at $5241.4 Million in 2026 and projected to reach to $10349.2 Million by 2031, representing a compound annual growth rate of 12.0%. Europe's cancer biomarkers market is positioned for sustained growth through 2031, driven by increasing adoption of precision oncology practices and robust healthcare infrastructure investments.

Europe Cancer Biomarkers Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Europe Cancer Biomarkers Market Trends and Insights

  • This growth trajectory in Europe reflects increasing adoption of precision oncology, rising healthcare investments, and strengthened regulatory frameworks across EU member states.
  • Europe's advanced healthcare infrastructure and emphasis on early cancer detection are driving demand for innovative biomarker solutions. The European market benefits from strong clinical research networks, collaborative healthcare systems, and growing reimbursement support for biomarker-driven diagnostics.
  • Europe's aging population and prevalence of cancer cases are accelerating the need for accurate diagnostic tools and personalized treatment approaches.
  • Between 2026 and 2031, Europe is expected to maintain momentum through technological advancements in liquid biopsy, genomic sequencing, and AI-enabled biomarker discovery. Europe's regulatory environment, including CE marking and IVDR compliance, continues to shape market dynamics while ensuring quality standards.
  • The region's commitment to cancer prevention and early intervention strategies positions Europe as a key growth market for cancer biomarker innovations..

Key Market Statistics

  • CAGR (2026-2031) 12.0% CAGR
  • Market Size, 2026 ~USD 5241.4 Million
  • Forecast, 2031 ~USD 10349.2 Million
  • Geography Europe

Europe Cancer Biomarkers Market Overview

Strong Market Valuation :

Europe's cancer biomarkers market is valued at $5,241.4 million in 2026, with Germany leading at $4,033.6 million, followed by the UK at $2,965.1 million, demonstrating significant regional concentration in Western Europe.

Accelerated Growth Trajectory :

The European market is expanding at a 12.0% CAGR, outpacing the global average of 11.6%, driven by increased precision oncology adoption and substantial healthcare investments across EU member states.

Regulatory Framework Strengthening :

Enhanced regulatory frameworks across EU member states are facilitating faster biomarker validation and clinical adoption, creating a favorable environment for market expansion and innovation in cancer diagnostics.

Forecast Growth to 2031 :

The European market is projected to nearly double, reaching $10,349.2 million by 2031, reflecting sustained demand for advanced diagnostic solutions and personalized cancer treatment approaches across the continent.

Europe Cancer Biomarkers Market Dynamics

  • The region benefits from advanced regulatory frameworks, strong clinical research capabilities, and high healthcare spending, particularly in Germany, the UK, and France.
  • These factors support rapid biomarker validation and clinical implementation. The market expansion is further supported by rising cancer incidence rates, growing awareness of personalized medicine benefits, and collaborative initiatives among European healthcare systems.
  • Continued investment in genomic research, coupled with favorable reimbursement policies in key markets, will sustain the 12.0% CAGR through 2031, positioning Europe as a critical hub for cancer biomarker innovation and adoption..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    In Vitro Diagnostics

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Enzyme-Linked Immunosorbent Assay (ELISA)
    • Dna Microarrays
    • Assay Kits
    • Microarrays
    Top Companies
    • ROCHE HOLDINGS AG
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Abbott Laboratories
    • Biomerieux s.a.

      Key Takeaways

      • Europe's cancer biomarkers market will nearly double from $5,241.4M (2026) to $10,349.2M (2031) at a 12.0% CAGR.
      • Europe's advanced healthcare infrastructure and precision oncology adoption are primary growth catalysts for biomarker demand.
      • Europe's regulatory frameworks and reimbursement policies are strengthening market accessibility and clinical adoption.
      • Europe's aging population and cancer prevalence drive sustained investment in early detection and personalized treatment biomarkers.

      Cancer Biomarkers Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment LUNG CANCER (Cancer Type)
      Forecast Period 2026–2031
      Growth Rate CAGR of 11.6% from 2026 to 2031
      Largest Segment OMICS TECHNOLOGIES (Profiling Technology)
      Market Size Base Year (Billions) ~USD 28.2 (2026)
      Revenue Forecast (Billions) ~USD 48.82 (2031)
      Segments Covered Profiling Technology, Type, Cancer Type, Products

      Europe Cancer Biomarkers Market Report Segmentation

      4 segment dimensions are covered across the global market.

      By Profiling Technology

      • Imaging Technologies
      • Omics Technologies

      By Type

      • 2D Gel Electrophoresis
      • Antibodies
      • Biopsy Instruments
      • Computed Tomography (Ct)
      • Genomics
      • Imaging Instruments
      • Immunoassay
      • In-Situ Hybridization (Ish)
      • Kits And Reagents
      • Magnetic Resonance Imaging (Mri)
      • Mammography
      • Mass Spectrometry
      • Next Generation Sequencing
      • Other Omics Technologies
      • Other Proteomics Technologies
      • Pathology-Based Instrument
      • Polymerase Chain Reaction
      • Positron Emission Tomography (Pet)
      • Probes
      • Protein Microarray
      • Proteomics
      • Ultrasound Imaging

      By Cancer Type

      • Bladder Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Kidney Cancer
      • Leukemia
      • Lung Cancer
      • Melanoma
      • Non-Hodgkin'S Lymphoma
      • Other Cancer Types
      • Prostate Cancer
      • Thyroid Cancer

      By Products

      • Bioinformatics Software
      • Consumables
      • Instruments

      REST OF EUROPE: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032

      Segment20242025202620272029203020312032CAGR (%)
      BIOPHARMACEUTICAL COMPANIES & CROS421.4445.5477.5513.7601.5656.4720.9792.48.8
      DIAGNOSTIC LABORATORIES1023.81068.21129.91199.41367.11471.91594.41728.57.3
      OTHER END USERS75.977.179.482.188.592.697.4102.54.4
      RESEARCH AND ACADEMIC INSTITUTES252.3265.5283.1303.1351.4381.5416.94568.3
      TOTAL1773.41856.319702098.22408.42602.42829.73079.47.7

      EUROPE: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032

      Segment20242025202620272029203020312032CAGR (%)
      BIOPHARMACEUTICAL COMPANIES & CROS1439.91574.91746.51943.724362750.43124.93553.412.6
      DIAGNOSTIC LABORATORIES3456.73731.34083.24484.15470.26092.76827.9765811.1
      OTHER END USERS257269.4286.1304.7348.9376.1407.6441.67.5
      RESEARCH AND ACADEMIC INSTITUTES835.3908.51001.91108.81374.215431743.41971.611.9
      TOTAL5988.96484.27117.67841.39629.310762.312103.813624.611.4

      Target Audience

      • In Vitro Diagnostics (IVD) Manufacturers : Need detailed European market data to develop biomarker assay portfolios, navigate EU regulatory requirements, and identify partnership opportunities with healthcare providers across key markets.
      • Pharmaceutical & Oncology Companies : Require market intelligence on biomarker adoption rates and clinical implementation trends to support companion diagnostic development and precision medicine commercialization strategies in Europe.
      • Healthcare Investors & Private Equity : Seek comprehensive market analysis and growth forecasts to evaluate investment opportunities in European biomarker companies, diagnostic platforms, and precision oncology ventures.
      • Hospital & Laboratory Networks : Need market insights to guide biomarker testing infrastructure investments, technology adoption decisions, and service expansion planning across European healthcare systems.
      • Healthcare Consultants & Strategy Firms : Require validated regional data and market forecasts to support client advisory work on precision oncology strategies, market entry planning, and competitive positioning in Europe.

      Key Companies in the Europe Cancer Biomarkers Market

      CompanyHQOwnershipStrongest segments
      NANOSTRING TECHNOLOGIES, INCUnited States
      CELL SIGNALING TECHNOLOGY, INC.United States
      TRANSGENOMIC, INC.United States
      SANOFISpain
      SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging-based biomarker systems and software,In-vitro diagnostics instruments and consumables,Varian oncology platforms and services,
      BECTON, DICKINSON AND COMPANYUnited StatesPublic CompanyInstruments (flow cytometers, analyzers, automation),Consumables & reagents (antibodies, kits, collection products, media),
      MYRIAD GENETICSUnited StatesPublic CompanyHereditary cancer and germline oncology tests (e.g., MyRisk, BRACAnalysis CDx),Tumor-based prognostic and companion diagnostics (MyChoice CDx, Prolaris, EndoPredict, Precise Tumor),Other oncology-adjacent genomics and lab services within cancer workflows,
      SYSMEX CORPORATIONJapanPublic CompanyInstruments (hematology, coagulation, cell analysis platforms),Consumables (reagents, calibrators, controls, software-linked services),
      HOLOGIC, INC.United StatesPrivate CompanyBreast cancer imaging systems and software,Biopsy guidance systems and markers,Cytology and related consumables (ThinPrep),

      NANOSTRING TECHNOLOGIES, INC

      NanoString Technologies develops and commercializes molecular analysis platforms for gene expression profiling and genomic research.

      CELL SIGNALING TECHNOLOGY, INC.

      Cell Signaling Technology Inc. produces research antibodies, proteins, and assay kits for cell biology and life sciences research.

      TRANSGENOMIC, INC.

      Transgenomic Inc. provides genetic testing and molecular diagnostics solutions for disease detection and management.

      SANOFI

      Sanofi is a multinational pharmaceutical company developing and marketing medicines, vaccines, and diagnostic products.

      SIEMENS HEALTHINEERS AG

      Siemens Healthineers AG is a global medical technology company providing diagnostic imaging, laboratory diagnostics, and healthcare IT solutions.

      BECTON, DICKINSON AND COMPANY

      Becton, Dickinson and Company manufactures and distributes medical devices, laboratory equipment, and diagnostic systems.

      MYRIAD GENETICS

      Myriad Genetics is a molecular diagnostics company providing genetic testing and precision medicine solutions for cancer and other diseases.

      SYSMEX CORPORATION

      Sysmex Corporation manufactures and sells hematology, hemostasis, and clinical chemistry diagnostic systems and reagents.

      HOLOGIC, INC.

      Hologic Inc. develops and markets diagnostic and medical imaging systems, particularly for women's health and cancer detection.

      Europe vs. other regions

      HowEurope compares to the other 3 regional blocs covered in this market.

      North America
      ~USD 16517.1 Million · 11.5% wtd CAGR ·
      Asia Pacific
      ~USD 10318.4 Million · 14.4% wtd CAGR ·
      Latin America
      ~USD 2334.9 Million · 10.5% wtd CAGR ·
      Middle East & Africa
      ~USD 1366.4 Million · 9.9% wtd CAGR ·

      Countries within Europe - compare and drill down

      Country2025 size (native)
      GermanyUSD 4033.6 Million
      UKUSD 2965.1 Million
      FranceUSD 1156.3 Million
      ItalyUSD 833.1 Million
      SpainUSD 699.2 Million
      RoeUSD 2328.7 Million

      Country market size visualization

      Germany
      USD 4033.6 Million
      UK
      USD 2965.1 Million
      France
      USD 1156.3 Million
      Italy
      USD 833.1 Million
      Spain
      USD 699.2 Million
      Roe
      USD 2328.7 Million

      Reasons to Buy this Report

      • Regional Market Leadership Data : Gain detailed insights into Europe's $5.2B market with country-level breakdowns for Germany ($4.0B), UK ($3.0B), France ($1.2B), and Italy ($833M), enabling precise market positioning and competitive analysis.
      • Growth Opportunity Identification : Leverage the 12% CAGR forecast through 2031 to identify high-growth segments and emerging opportunities in precision oncology across EU markets with strengthened regulatory frameworks.
      • Strategic Market Entry Planning : Develop targeted go-to-market strategies for European expansion with comprehensive analysis of regulatory environments, healthcare infrastructure, and reimbursement landscapes across key markets.
      • Competitive Intelligence : Understand market dynamics and competitive positioning within Europe's leading biomarker markets, including insights into adoption rates and clinical implementation trends by country.
      • Investment Decision Support : Make informed investment and partnership decisions with validated market sizing, growth projections, and regional performance metrics specific to European cancer biomarker segments.

      Frequently asked questions

      What is the projected market size for cancer biomarkers in Europe by 2031?

      Europe's cancer biomarkers market is projected to reach $10,349.2 million by 2031, growing from $5,241.4 million in 2026.

      What is the CAGR for Europe's cancer biomarkers market?

      Europe's cancer biomarkers market is expected to grow at a compound annual growth rate of 12.0% between 2026 and 2031.

      What factors are driving growth in Europe's cancer biomarkers market?

      Europe's market growth is driven by precision oncology adoption, advanced healthcare infrastructure, aging populations, regulatory support, and increased reimbursement for biomarker diagnostics.

      How does Europe's regulatory environment impact the cancer biomarkers market?

      Europe's CE marking requirements and IVDR compliance ensure quality standards while facilitating market entry and clinical adoption of biomarker solutions.

      Which technologies are emerging in Europe's cancer biomarkers market?

      Liquid biopsy, genomic sequencing, AI-enabled biomarker discovery, and personalized treatment approaches are key emerging technologies in Europe's market.

      RESEARCH METHODOLOGY

      The objective of the study is to analyze key market dynamics, including drivers, opportunities, restraints, challenges, and key players' strategies. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players, the competitive landscape of the cancer biomarkers market will be analyzed, and market players will be evaluated on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation were used.
      The four steps involved in estimating the market size are

      Secondary Research

      In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

      Primary Research

      In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess prospects.

      The following is a breakdown of the primary respondents

      Cancer Biomarkers Market Size, and Share

      Note 1: Others include sales, marketing, and product managers.
      Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.

      COMPANY NAME

      DESIGNATION

      Thermo Fisher (US)

      Sales Manager

      F. Hoffmann-La Roche AG (Switzerland)

      Product Manager

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total market size of cancer biomarkers. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • The key players in the industry have been identified through extensive secondary research
      • The revenues generated by leading players operating in the cancer biomarkers market have been determined through primary and secondary research
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

      Cancer Biomarkers Market : Top-Down and Bottom-Up Approach

      Cancer Biomarkers Market Top Down and Bottom Up Approach

      Data Triangulation

      After arriving at the overall market size using the process described above, the total market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      Cancer biomarkers are biological molecules produced by the body or a tumor in a person with cancer. Cancer biomarker testing helps differentiate alterations in the tumor. Biomarkers may be produced by the cancer tissue itself or by other cells in the body in response to cancer. It can also be found in the blood, stool, urine, tumor tissue, or other tissues or bodily fluids. Biomarkers can be DNA, RNA, proteins, or metabolomic profiles specific to the tumor. They enhance cancer detection and facilitate high-speed, noninvasive diagnosis using profiling technologies such as omics, imaging, immunoassays, and cytogenetics.

      Key Stakeholders

      • Product Manufacturers, Distributors, and Suppliers
      • Diagnostic Laboratories
      • Research Laboratories and CROs
      • Ambulatory Testing Centers
      • Contract Testing Laboratories
      • Academic Universities and Medical Research Centers
      • Research and Development (R&D) Centers

      Report Objectives

      • To define, segment, and forecast the cancer biomarkers market by profiling technology, cancer type, product, application, end user, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market 
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the market segments with respect to six regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries
      • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
      • To benchmark players within the market using the proprietary company evaluation matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
      • To study the impact of AI on the market, along with the macroeconomic outlook for each region

      Available customizations:

      MarketsandMarkets offers the following customizations for this market report.

      Product Analysis

      • Product matrix, which provides a detailed comparison of the product portfolio of each company in the cancer biomarkers market

      Country Information

      • Additional country-level analysis of the cancer biomarkers market

      Company Profiles

      • Additional five company profiles of players operating in the cancer biomarkers market.

      Get the Full Cancer Biomarkers Market Report

      Full forecast, segment splits, and company analysis for all Cancer Biomarkers Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status